Leader in Transdermal Technology Research and Development and Solution for Soluble Microneedle Drug Delivery
BIOQINGLAM is a R&D-driven enterprise focusing on the R&D and industrialization of soluble microneedle drug delivery technology. Microneedle drug delivery technology is a complicated system engineering, involving MEMS, coating process, pharmaceutics, materials science, molecular biology, biochemistry, industrial engineering and other multidisciplinary and multi-field technologies. Application of the microneedle drug delivery technology requires strong capabilities of system integration. BIOQINGLAM team has 15 years of experience in project R&D and industrialization, and firmly practice the concept of the Design for Six Sigma (DFSS). In 2021, we got successes from the research of the soluble microneedles delivery for gene drugs in cooperation with our customers. At present, we are working with several listed pharmaceutical companies to develop microneedle-drugs, which include genetic vaccines, inactivated vaccines, proteins, polypeptide and chemical drugs. We combine closely research and development with industrialization, and have built and put into operation a GMP workshop dedicated to R&D of drugs. We provide technical outputs to our customers that can only be successfully industrialized.
"It starts small."
"It starts small."
Microneedle-mediated drug delivery for biopharmaceuticalSuch drugs are direct-acting APIs that do not require further conversion in the body, such as monoclonal antibodies and peptides. The focus of microneedle preparations of such drugs is on stabilizing the preparation and accurately quantifying intradermal administration.
Microneedle-mediated drug delivery for generic drugsGenetic drugs include DNA and mRNA therapeutics, and in addition to the stability development of microneedle preparations, the activities of such drugs also required to be controlled in vivo through microneedle preparations, and we already have successful case of such drugs.
Microneedle-mediated drug delivery for water-soluble chemicalsBIOQINGLAM has accumulated rich experience in the development of microneedle preparations for such drugs, and the selection space for formulation matching is also the largest, we know how to complete the preparation of microneedle finished products in a short time.
Microneedle-mediated drug delivery for poorly water-soluble chemicalsThe amount of intradermal body fluid is far less than gastric juice, intestinal juice, intramuscular injection, intravenous injection, and other routes of administration; therefore how to make the trace amount of intradermal body fluid transport slowly dissolving poorly dissolving drugs to the whole body is facing massive technical challenges. At present, BIOQINGLAM has found a feasible technical route to achieve poorly soluble microneedle preparations.
Lin JiangFounder of the Company / Doctor of Organic Chemistry, Chinese Academy of SciencesHe is the founder of the company, doctor of organic chemistry from Chinese Academy of Sciences, leader of research and development and industrialization of transdermal drug delivery technology of soluble microneedles, and the founder, executive director and general manager of Shenzhen Qinglan Biotechnology Co., Ltd., and has obtained more than 40 national authorized invention patents. He focuses on the research and development on microneedle delivery vaccine and the solutions for new drug research and development of microneedle patches.More
Xingyou LiQuality Operation DirectorBachelor of Science in Analytical Chemistry, Department of Chemistry, Jilin University.More
He has set up 3 testing laboratories and participated in the hardware and GMP software construction of 3 pharmaceutical enterprises. He has 16 years of laboratory experience and 22 years of quality management experience in the pharmaceutical industry. Involving ISO 9001 certification, CNAS accreditation, WHO-PQ certification, GMP certification at home and abroad, etc., he has rich experience in GMP auditing.
Many years of experience in biological products, traditional Chinese medicine preparations, chemical preparations and other fields. The pharmaceutical dosage forms involved are: sterile lyophilized powder injection, small volume injection, tablets, capsules, soft capsules, granules, etc.
Participated in the quality research of multiple biologics projects and obtained two drug clinical research approvals.
Organized and completed two drug production technology transfer projects, and obtained 6 drug supplement application approvals.
Venus PoonR&D DirectorShe has more than ten years experience in the R&D, registration, and management of new drug preparations, she has been responsible for and managed drug research and development and registration from innovative drug preparation research and development, the declaration to full life cycle management in several pharmaceutical companies.More
Familiar with the R&D, application, and registration requirements of innovative drug preparations, also familiar with the registration requirements of biopharmaceutical IND and BLA. Has been responsible for the development, quality research, and registration application of a number of innovative drug preparations.
Serving as the company's R&D director, responsible for the company's R&D of new drug preparation, and quality research.
Principle and advantages of microneedle drug delivery technology
According to the latest professional literature, microneedle technology includes solid needle, hollow needle, coated needle, soluble microneedle and swelling needle. Based on its own research and development practices, BIOQINGLAM is optimistic about the application of soluble microneedle technology in drug delivery and diagnosis. Microneedle drug delivery technology is a practical science and a results-oriented technology.
Painless and non-invasive, patient compliance is the highest, user experience is similar to band-aids, no need for professionals' guidance or help, patients could operate it themselves.
The dosage is reduced to 1/5 to 1/200 of the dosage of traditional dosage forms ,As the dosage decreases sharply, side effects are negligible.
The delivery of vaccine with microneedle patches has been proven to trigger an enhanced immune response and save dose. In addition, microneedle drug delivery has been shown to enhance the pharmacokinetic and pharmacodynamic effects of certain drugs.
Microneedling drug delivery is adequate for a wide range of active (therapeutic and vaccine) and inactive compounds, including small molecules, nucleic acids, peptides, proteins, and micro/nanoparticles.
The proprietary formulation and manufacturing process have proven that our microneedle patches maintain the stability of their pharmaceutical actives at room temperature, thereby reducing or so far as to eliminate the cold chain.
Microneedle drug delivery technology is a kind of dosage form technology and an innovative way of drug delivery. It is an innovative dosage form juxtaposed with tablets, capsules and injections. All drugs need a dosage form before they can be used by patients. In the past, drug developers could only choose conventional dosage forms such as tablets, capsules and injections. Now, soluble microneedle drug delivery technology has solved the industrialization problem, providing drug developers with a new dosage form.
R&D cooperation with Innovative pharmaceutical enterprises
Innovative pharmaceutical enterprise R & D cooperation
The dosage, course of treatment, curative effect, toxic and side effects of almost any type of drugs using microneedle dosage form need to be re-recognized and understoodMore
R&D cooperation on generic drugs
Generic drug R & D cooperation
Generic drug companies choose the combination of conventional drugs and microneedle dosage forms, which is a breakthrough direction, and the risk of R&D failure is sharply reducedMore
R&D cooperation on in vitro diagnosis
Innovative pharmaceutical enterprise R & D cooperation
The corresponding biosensor can be modified on the microneedle patch to amplify the marker signal, which can be used for rapid in-situ multichannel diagnosisMore
JUL 2021 Received 10 million yuan (angel round) investment from Beijing Advaccine Biotechnology Co., Ltd.
JUL 2022 Led by Jiaxing TianfuHuasheng Equity Investment Partnership (Limited Partnership), followed by Beijing Advaccine Biotechnology Co., Ltd., received a total of 25 million yuan (pre-A round) investment.
JUN 2023 A round of financing (the 3rd round)